Content Status
Type
Linked Node
Interim reports of DR-TB Treatment
Learning ObjectivesExplain the interim report, and why it is important. Criteria to be fulfilled, how to interpret, and what does it mean? Explain the decisive importance of the interim reports.
As Drug-resistant TB (DR-TB) treatment is of relatively long duration, the interim treatment reports are prepared in Ni-kshay to assess the interim treatment outcomes in the programme.
Criteria
- The interim report assessment period is six calendar months, usually counted from January to the end of June and July to the end of December.
- All patients registered and starting treatment during the assessment period are included in the calculation.
Interpretation
- Interim results of DR-TB patients who started treatment during the first semester of a year (1 January to 30 June), should be calculated at the beginning of April of the following year.
- The interim report form should be completed 9 months after the closing day of the cohort so as to allow culture information at 6 months of treatment to be included for all patients in the cohort.
| Sl. No. | DR-TB Regimen | Time point for interim reporting | Cohort for interim evaluation, reporting and monitoring (Here ‘X’ is the reporting month) | If reporting month is X= April 2023, following are the corresponding cohort for interim report evaluation |
| 1 | Isoniazid (H) - mono/ poly DR-TB regimen | 4th month of treatment | X - 6 months | Cohort of October 2022 and previous |
| 2 | Shorter oral Bedaquiline-containing Multidrug-resistant (MDR)/ Rifampicin-resistant (RR)-TB regimen | 4th month of treatment | X - 6 months | Cohort of October 2022 and previous |
| 3 | Longer oral Multidrug-resistant/ Extensively Drug-resistant TB (M/XDR-TB) regimen | 6th month of treatment | X - 10 months | Cohort of June 2022 and previous |
| 4 | BPal (Bedaquiline, Pretomanid, Linezolid) regimen | 4th month of treatment | X - 6 months | Cohort of October 2022 and previous |
| 5 | Prior longer M/XDR-TB regimen (Drug Susceptibility Testing (DST) guided regimen) | 6th month of treatment | X - 10 months | Cohort of June 2022 and previous |
Importance
-
Culture conversion (for confirmed DR-TB cases) and death by six months are important predictors of final outcomes.
-
It also provides early information on the number of patients initiated on second-line drugs for MDR-TB that turned out not to be XDR.
-
Information on treatment interruption at the end of six months is important for programme review and implementing corrective actions.
-
Overall interim reports are important for supervision, monitoring and evaluation at all programmatic levels.
Resources
-
Guidelines on Programmatic Management of Drug-resistant TB (PMDT) in India, 2021, CTD, MoHFW, India.
Assessment
| Question | Answer 1 | Answer 2 | Answer 3 | Answer 4 | Correct answer | Correct explanation | Page id | Part of Pre-test | Part of Post-test |
| What is the duration of the assessment of the interim report in NTEP? | 2 Calendar months | 3 Calendar months | 6 Calendar months | 12 Calendar months | 3 | The interim report assessment period is six calendar months, usually counted from January to the end of June and July to the end of December. | Yes | Yes |
Content Creator
Reviewer
Target Audience
- Log in to post comments